First-line (1L) osimertinib in EGFR mutant (mut) advanced non-small cell lung cancer (aNSCLC) patients (pts): Progression (PD) pattern and safety in the real-world (RW)

被引：0
|
作者：
Lorenzi, M. [1 ]
Dal Maso, A. [1 ]
Ferro, A. [1 ]
Polo, V. [2 ]
Scattolin, D. [1 ]
Macerelli, M. [3 ]
Follador, A. [3 ]
Targato, G. [3 ]
Indraccolo, S. [4 ]
Frega, S. [5 ]
Menis, J. [1 ]
Bonanno, L. [5 ]
Guarneri, V. [1 ]
Conte, P. F. [1 ]
Pasello, G. [1 ]
机构：
[1] Univ Padua, Dept Surg Oncol & Gastroenterol, Padua, Italy
[2] Ca Foncello Hosp, Oncol Unit, AULSS 2 Marca Trevigiana, Treviso, Italy
[3] Azienda Sanit Univ Integrata Udine, Santa Maria Misericordia Hosp, Dept Med Oncol, Udine, Italy
[4] Veneto Inst Oncol IOV IRCCS, Immunol & Mol Oncol Unit, Padua, Italy
[5] Veneto Inst Oncol IOV IRCCS, Div Med Oncol 2, Padua, Italy
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
149P
引用
收藏
页码：S779 / S779
页数：1
相关论文
共 50 条
  • [31] Real-World Experience of First-Line Osimertinib in EGFR Mutated Non-Small Cell Lung Cancers from a Tertiary Cancer Center, India
    Tiwari, Atul
    Singh, Ajay Kumar
    Noronha, Vanita
    Patil, Vijay M.
    Menon, Nandini
    Shah, Minit J.
    Shah, Darshit
    Jobanputra, Kunal
    Trikha, Mehak
    Ubharay, Ahmad
    Yadav, Shashikant
    Majumdar, Anuradha
    Chandrani, Pratik
    Kumar, Rajiv K.
    Pai, Trupti
    Janu, Amit
    Purandare, Nilendu
    Prabhash, Kumar
    SOUTH ASIAN JOURNAL OF CANCER, 2024,
  • [32] Real-world treatment sequencing in advanced non-small cell lung cancer (aNSCLC).
    Radtchenko, Janna
    Feinberg, Bruce A.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [33] A multicenter, real-world study on effectiveness and safety of first-line modified PD-1 inhibitors with chemotherapy in advanced non-small cell lung cancer (aNSCLC) with drive gene-negative
    Li, Tao
    Chen, Chao
    Liu, Lu
    Qin, Jiapei
    Qiu, Lupeng
    Wang, An
    Dong, Weiwei
    Zhang, Gehan
    Li, Yao
    Zhao, Lei
    Zhang, Fan
    Hu, Yi
    CANCER MEDICINE, 2024, 13 (03):
  • [34] Real-world efficacy and safety of anlotinib in combination with PD-1/PD-L1 inhibitors as first-line or second-line treatment in advanced non-small cell lung cancer
    Wang, Q.
    Ma, C.
    Wang, T.
    Chen, G.
    Wang, H.
    Mei, J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1063 - S1063
  • [35] Real-world efficacy and safety of anlotinib in combination with PD-1/PD-L1 inhibitors as first-line or second-line treatment in advanced non-small cell lung cancer
    Shang, X. Q.
    Wang, T.
    Chen, G.
    Ma, C.
    Wang, H.
    Jia, X.
    Mei, J.
    ANNALS OF ONCOLOGY, 2022, 33 : S1550 - S1550
  • [36] Amivantamab plus lazertinib vs. osimertinib in first-line EGFR-mutant advanced non-small cell lung cancer
    Hasan, Nazmul
    Nagasaka, Misako
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2025, 19 (03) : 223 - 232
  • [37] Real-World Clinical Outcomes in Patients with Advanced Non-Small Cell Lung Cancer (aNSCLC) in the US
    Nadler, E.
    Chang, J.
    Zhang, X.
    Aguilar, K.
    Zhou, J.
    Arondekar, B.
    Pawar, V.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S38 - S39
  • [38] Real-world management patterns in EGFR-mutant advanced non-small-cell lung cancer before first-line adoption of osimertinib: the REFLECT study in Greece
    Lampaki, Sofia
    Mountzios, Giannis
    Georgoulias, Vassilis
    Rapti, Aggeliki
    Xanthakis, Ioannis
    Baka, Sofia
    Mavroudis, Dimitrios
    Samantas, Epaminondas
    Athanasiadis, Elias
    Zagouri, Flora
    Charpidou, Andriani
    Somarakis, Alvertos
    Papista, Christina
    Nikolaou, Aristeidis
    Anastasopoulou, Eleftheria
    Paparepa, Zoe
    Syrigos, Konstantinos N.
    FUTURE ONCOLOGY, 2022, 18 (28) : 3151 - 3164
  • [39] Multicentered Real-World Evidence of Osimertinib Treatment in EGFR-Mutant Advanced Non-Small Cell Lung Cancer (NSCLC) In Thailand
    Thamrongjirapat, T.
    Sitthideatphaiboon, P.
    Oranratnachai, S.
    Khiewngam, K.
    Maneenil, K.
    Prasongsook, N.
    Korphaisarn, K.
    Wangsubtawee, S.
    Rattanaphom, A.
    Reungwetwattana, T.
    Sriuranpong, V.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S624 - S625
  • [40] Long-term survival and treatment (tx) patterns after first-line (1L) osimertinib in patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive (m) advanced non-small cell lung cancer (NSCLC): Japanese cohort of a global real-world (rw) observational study
    Fujimoto, D.
    Takiguchi, Y.
    Matsumoto, S.
    Yamamoto, N.
    Saito, G.
    Nishimura, Y.
    Sugiyama, S.
    Oku, A.
    Karia, P.
    Antunes, L.
    Chapaneri, J.
    Salomonsen, R. J-B.
    Martin, E.
    Okhuoya, P.
    Muto, M.
    ANNALS OF ONCOLOGY, 2023, 34 : S1657 - S1658
12345